

Elekta Holds First Meeting of the MOSAIQ® RTP Particle Therapy Global Council

Stockholm, March 17, 2009 - Elekta, a human care company pioneering significant innovations and clinical solutions for treating cancer and neurological conditions, announces the successful conclusion of the 1st meeting of the MOSAIQ® Radiation Treatment Planning (RTP) Particle Therapy Global Council.

Set within the wonderful Scenery of Courmayeur in the Italian Alps, the goal and achievement of the meeting was to develop robust planning tools in all Particle Therapy environments including Protons and Carbon ions within the MOSAIQ RTP framework. A collaborative discussion placed strong emphasis on Workflow Optimization and Integration with the EMR and how to improve Outcome Analysis and Evidence Based Medicine in Particle Therapy.

The council included representatives from industry leaders in the Particle Therapy field including Elekta and IBA, as well as innovators from ProCure, Trento, Oklahoma, NIRS-Japan and the University of Tuebingen. Participation from additional Particle Therapy leading centers is expected for the next Council meeting to be held during the 48th PTCOG in Heidelberg, Germany, September 2009.

The support of IBA Particle Therapy was greatly appreciated by members of the Elekta Group including Elekta Oncology, Impac Software, and CMS Software. The success of the meeting confirms the leadership of the two companies in the continuous development of a common strategy in the Particle Therapy field.

For further information, please contact:

Ian Shaw, Business Marketing Manager, Particle Therapy

Tel: +44 1293 654 135, e-mail: ian.shaw@elekta.com

David Murphy, Director of Marketing and Communications, Treatment Planning,

Tel: +1 314.812.4320, email : dmurphy@cmsrtp.com

About Elekta

Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated state of the art tools and treatment planning systems for radiation therapy and radiosurgery, as well as workflow enhancing software systems across the spectrum of cancer care.

Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to help in the cure of cancer patients with curable disease and to improve the quality of life of those patients with metastatic disease, making the future possible today.

Today, Elekta solutions in oncology and neurosurgery are used in over 5,000 hospitals

globally, and every day more than 100,000 patients receive diagnosis, treatment or follow-up with the help of a solution from the Elekta Group.

Elekta employs around 2,500 employees globally. The corporate headquarter is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTA. For more information about Elekta, please visit www.elekta.com.

About IBA

IBA develops and markets leading edge technologies, pharmaceuticals and tailor-made solutions for healthcare with a focus on cancer diagnosis and therapy. Leveraging on its scientific expertise, IBA is also active in the field of industrial sterilization and ionization. Listed on the pan-European stock exchange EURONEXT, IBA is included in the BelMid Index. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

Website: <http://www.iba-worldwide.com>